Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Hamburg Tries To “Cope” With FDA Budget, Emphasizes Predictability

This article was originally published in The Tan Sheet

Executive Summary

The commissioner says FDA cannot operate effectively without predictable budgets, just as industry needs consistent FDA policy and actions for successful drug development. Making sequestered user fees available could be accomplished in fiscal 2014 budget negotiations.

You may also be interested in...

FDA Shutdown Lands Hard On CFSAN-Regulated Industries

The federal shutdown interrupts FDA’s increasing enforcement against firms marketing violative supplement products in addition to slowing drug application evaluations and facility inspections. FDA would retain 8,180 staff members, about 55% of its total, mostly because they could be “paid from carryover funding.”

FDA Accelerated Approval For Rare Diseases Again Under Congressional Pressure

Letter being circulated by Rep. Bilirakis states the agency’s draft expedited approval guidance does not provide clarity for rare disease sponsors to use accelerated approval.

FDA Budget Faces $319 Million Cut Under Sequestration

The estimated reduction, included in the White House OMB’s report to Congress, is equal to the cost of 900 to 1,200 agency employees, an agency advocate says. The across-the-board cuts loom with the failure of the congressional Super Committee to find $1.2 trillion in cuts over 10 years.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts